 Christopher Striebich
Concepts (163)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Arthritis, Rheumatoid | 15 | 2026 | 1180 | 1.210 |
Why?
| | Antirheumatic Agents | 4 | 2026 | 307 | 0.640 |
Why?
| | Hydroxychloroquine | 2 | 2026 | 65 | 0.440 |
Why?
| | Anti-Citrullinated Protein Antibodies | 3 | 2026 | 127 | 0.370 |
Why?
| | Susac Syndrome | 1 | 2011 | 3 | 0.340 |
Why?
| | Pregnancy Complications, Cardiovascular | 1 | 2011 | 85 | 0.320 |
Why?
| | B-Lymphocytes | 4 | 2025 | 872 | 0.280 |
Why?
| | Interferon-alpha | 2 | 2021 | 193 | 0.260 |
Why?
| | Rheumatoid Factor | 4 | 2022 | 178 | 0.250 |
Why?
| | Lupus Erythematosus, Systemic | 2 | 2025 | 238 | 0.250 |
Why?
| | Autoantibodies | 6 | 2023 | 1509 | 0.240 |
Why?
| | Endothelium, Vascular | 1 | 2011 | 956 | 0.210 |
Why?
| | Meniscus | 1 | 2023 | 23 | 0.190 |
Why?
| | Rheumatology | 1 | 2023 | 133 | 0.180 |
Why?
| | Autoimmune Diseases | 2 | 2019 | 469 | 0.160 |
Why?
| | Disease Progression | 2 | 2025 | 2865 | 0.160 |
Why?
| | Receptors, Antigen, T-Cell, alpha-beta | 2 | 2002 | 334 | 0.160 |
Why?
| | STAT1 Transcription Factor | 1 | 2021 | 66 | 0.160 |
Why?
| | Anterior Cruciate Ligament Injuries | 1 | 2023 | 218 | 0.160 |
Why?
| | Lovastatin | 1 | 2020 | 37 | 0.160 |
Why?
| | Methotrexate | 2 | 2021 | 233 | 0.150 |
Why?
| | Osteoarthritis, Knee | 1 | 2023 | 281 | 0.150 |
Why?
| | STAT3 Transcription Factor | 1 | 2021 | 206 | 0.140 |
Why?
| | Interleukin-10 | 1 | 2021 | 311 | 0.140 |
Why?
| | Synovial Fluid | 1 | 1998 | 67 | 0.140 |
Why?
| | Arthroplasty, Replacement, Knee | 1 | 2023 | 376 | 0.130 |
Why?
| | C-Reactive Protein | 1 | 2020 | 423 | 0.130 |
Why?
| | Rheumatic Diseases | 1 | 2019 | 98 | 0.130 |
Why?
| | T-Lymphocytes | 1 | 2025 | 1998 | 0.130 |
Why?
| | CD4-Positive T-Lymphocytes | 2 | 2025 | 1146 | 0.120 |
Why?
| | Triage | 1 | 2019 | 250 | 0.120 |
Why?
| | Fatty Acids, Omega-3 | 1 | 2017 | 143 | 0.120 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2020 | 444 | 0.120 |
Why?
| | Autoimmunity | 2 | 2012 | 933 | 0.120 |
Why?
| | Inflammation | 2 | 2025 | 2884 | 0.110 |
Why?
| | Interferon-beta | 1 | 2015 | 92 | 0.110 |
Why?
| | Epitopes | 3 | 2023 | 473 | 0.110 |
Why?
| | Double-Blind Method | 3 | 2026 | 2064 | 0.110 |
Why?
| | Wrist Injuries | 1 | 2014 | 23 | 0.110 |
Why?
| | Ligaments, Articular | 1 | 2014 | 54 | 0.100 |
Why?
| | Antibodies, Monoclonal, Murine-Derived | 2 | 2011 | 95 | 0.100 |
Why?
| | Peptides, Cyclic | 3 | 2026 | 273 | 0.100 |
Why?
| | Middle Aged | 13 | 2026 | 36309 | 0.100 |
Why?
| | Rituximab | 2 | 2011 | 210 | 0.090 |
Why?
| | Adult | 11 | 2026 | 40881 | 0.090 |
Why?
| | Stress, Psychological | 1 | 2020 | 1151 | 0.090 |
Why?
| | Range of Motion, Articular | 1 | 2014 | 429 | 0.090 |
Why?
| | Bronchial Diseases | 1 | 2011 | 38 | 0.090 |
Why?
| | Treatment Outcome | 6 | 2025 | 11794 | 0.090 |
Why?
| | Muscle Strength | 1 | 2014 | 332 | 0.080 |
Why?
| | Humans | 22 | 2026 | 145783 | 0.080 |
Why?
| | Female | 16 | 2026 | 79045 | 0.080 |
Why?
| | Labor, Induced | 1 | 2011 | 40 | 0.080 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2015 | 1217 | 0.080 |
Why?
| | Cyclophosphamide | 1 | 2011 | 272 | 0.080 |
Why?
| | Genes, Immunoglobulin | 1 | 1990 | 29 | 0.080 |
Why?
| | Severity of Illness Index | 3 | 2025 | 2933 | 0.080 |
Why?
| | Immunoglobulins, Intravenous | 1 | 2011 | 133 | 0.080 |
Why?
| | Recovery of Function | 1 | 2014 | 716 | 0.080 |
Why?
| | Immune Tolerance | 1 | 2012 | 385 | 0.080 |
Why?
| | Health Fairs | 1 | 2009 | 10 | 0.080 |
Why?
| | Immunoglobulin Heavy Chains | 1 | 1990 | 86 | 0.080 |
Why?
| | Male | 15 | 2026 | 73011 | 0.080 |
Why?
| | Synovitis | 1 | 2009 | 35 | 0.070 |
Why?
| | Signal Transduction | 2 | 2021 | 5224 | 0.070 |
Why?
| | Drug Therapy, Combination | 1 | 2011 | 1043 | 0.070 |
Why?
| | Adrenal Cortex Hormones | 1 | 2011 | 484 | 0.070 |
Why?
| | Risk Factors | 4 | 2025 | 10919 | 0.070 |
Why?
| | Aspirin | 1 | 2011 | 406 | 0.070 |
Why?
| | Immunoglobulin M | 2 | 2022 | 265 | 0.060 |
Why?
| | Antibodies, Antinuclear | 1 | 2025 | 62 | 0.060 |
Why?
| | Biomarkers | 4 | 2021 | 4302 | 0.050 |
Why?
| | Lung Diseases | 1 | 2011 | 782 | 0.050 |
Why?
| | Aged | 6 | 2026 | 26217 | 0.050 |
Why?
| | Rheumatologists | 1 | 2023 | 15 | 0.050 |
Why?
| | Immunosuppressive Agents | 1 | 2008 | 838 | 0.050 |
Why?
| | Phosphorylation | 2 | 2021 | 1708 | 0.050 |
Why?
| | Immunoglobulin Isotypes | 1 | 2022 | 36 | 0.050 |
Why?
| | Complementarity Determining Regions | 1 | 2002 | 54 | 0.050 |
Why?
| | Colorado | 3 | 2020 | 4556 | 0.050 |
Why?
| | Clone Cells | 2 | 2002 | 263 | 0.040 |
Why?
| | Incidence | 2 | 2020 | 2934 | 0.040 |
Why?
| | Leukocytes, Mononuclear | 2 | 2021 | 574 | 0.040 |
Why?
| | Prospective Studies | 3 | 2022 | 8078 | 0.040 |
Why?
| | Mass Screening | 1 | 2009 | 1361 | 0.040 |
Why?
| | Abatacept | 1 | 2021 | 56 | 0.040 |
Why?
| | Immunoglobulin A | 1 | 2022 | 214 | 0.040 |
Why?
| | Epigenesis, Genetic | 1 | 2025 | 693 | 0.040 |
Why?
| | Antibodies, Monoclonal | 1 | 2008 | 1505 | 0.040 |
Why?
| | Young Adult | 4 | 2025 | 14254 | 0.040 |
Why?
| | Complement Activation | 1 | 2023 | 399 | 0.040 |
Why?
| | Joints | 2 | 2011 | 106 | 0.040 |
Why?
| | Sequence Analysis | 1 | 1998 | 34 | 0.040 |
Why?
| | Amino Acid Sequence | 2 | 2002 | 2131 | 0.040 |
Why?
| | Lymphocyte Activation | 1 | 2002 | 1133 | 0.030 |
Why?
| | Molecular Sequence Data | 2 | 2002 | 2883 | 0.030 |
Why?
| | Pregnancy | 1 | 2011 | 7216 | 0.030 |
Why?
| | HIV-1 | 1 | 2002 | 908 | 0.030 |
Why?
| | CD8-Positive T-Lymphocytes | 1 | 2002 | 923 | 0.030 |
Why?
| | Aged, 80 and over | 2 | 2021 | 8347 | 0.030 |
Why?
| | Base Sequence | 1 | 1998 | 2171 | 0.030 |
Why?
| | Odds Ratio | 1 | 2017 | 1083 | 0.030 |
Why?
| | Patient Selection | 1 | 2019 | 739 | 0.030 |
Why?
| | Lunate Bone | 1 | 2014 | 10 | 0.030 |
Why?
| | Scaphoid Bone | 1 | 2014 | 17 | 0.030 |
Why?
| | Survival Analysis | 1 | 2017 | 1378 | 0.030 |
Why?
| | Proportional Hazards Models | 1 | 2017 | 1330 | 0.030 |
Why?
| | Adolescent | 3 | 2025 | 22577 | 0.020 |
Why?
| | Case-Control Studies | 1 | 2021 | 3634 | 0.020 |
Why?
| | Syk Kinase | 1 | 2012 | 19 | 0.020 |
Why?
| | Longitudinal Studies | 1 | 2020 | 2968 | 0.020 |
Why?
| | Immunoglobulin D | 1 | 2012 | 29 | 0.020 |
Why?
| | Protein Tyrosine Phosphatase, Non-Receptor Type 11 | 1 | 2012 | 22 | 0.020 |
Why?
| | Tumor Necrosis Factor Receptor Superfamily, Member 7 | 1 | 2012 | 28 | 0.020 |
Why?
| | Clonal Anergy | 1 | 2012 | 52 | 0.020 |
Why?
| | Arthrography | 1 | 2011 | 19 | 0.020 |
Why?
| | Receptors, Antigen, B-Cell | 1 | 2012 | 130 | 0.020 |
Why?
| | Cross-Sectional Studies | 1 | 2023 | 5925 | 0.020 |
Why?
| | Antigens, CD19 | 1 | 2012 | 128 | 0.020 |
Why?
| | Risk Assessment | 1 | 2020 | 3752 | 0.020 |
Why?
| | Sensitivity and Specificity | 1 | 2015 | 2000 | 0.020 |
Why?
| | Cell Differentiation | 1 | 1998 | 2050 | 0.020 |
Why?
| | Retrospective Studies | 2 | 2022 | 17330 | 0.020 |
Why?
| | Predictive Value of Tests | 1 | 2015 | 2123 | 0.020 |
Why?
| | Blotting, Northern | 1 | 1990 | 203 | 0.020 |
Why?
| | Immunoglobulin Variable Region | 1 | 1990 | 80 | 0.020 |
Why?
| | Cross Reactions | 1 | 1990 | 130 | 0.020 |
Why?
| | Hybridomas | 1 | 1990 | 233 | 0.020 |
Why?
| | Antibody Specificity | 1 | 1990 | 179 | 0.020 |
Why?
| | Molecular Weight | 1 | 1990 | 312 | 0.020 |
Why?
| | Databases, Factual | 1 | 2015 | 1491 | 0.020 |
Why?
| | Autoantigens | 1 | 2012 | 427 | 0.020 |
Why?
| | Adaptor Proteins, Signal Transducing | 1 | 2012 | 426 | 0.020 |
Why?
| | Mice, Mutant Strains | 1 | 1990 | 302 | 0.020 |
Why?
| | Intracellular Signaling Peptides and Proteins | 1 | 2012 | 457 | 0.020 |
Why?
| | Seroepidemiologic Studies | 1 | 2009 | 171 | 0.020 |
Why?
| | Protein-Tyrosine Kinases | 1 | 2012 | 431 | 0.020 |
Why?
| | Multigene Family | 1 | 1990 | 210 | 0.020 |
Why?
| | Community-Institutional Relations | 1 | 2009 | 100 | 0.020 |
Why?
| | Structure-Activity Relationship | 1 | 1990 | 563 | 0.020 |
Why?
| | Early Diagnosis | 1 | 2009 | 251 | 0.020 |
Why?
| | Antigens, CD20 | 1 | 2008 | 34 | 0.020 |
Why?
| | Follow-Up Studies | 1 | 2017 | 5428 | 0.020 |
Why?
| | Lymphocyte Count | 1 | 2008 | 165 | 0.020 |
Why?
| | Lymphocyte Depletion | 1 | 2008 | 133 | 0.020 |
Why?
| | Prognosis | 1 | 2015 | 4330 | 0.020 |
Why?
| | HIV Infections | 1 | 2002 | 3195 | 0.020 |
Why?
| | Registries | 1 | 2015 | 2410 | 0.020 |
Why?
| | Gene Expression | 1 | 1990 | 1478 | 0.010 |
Why?
| | United States | 1 | 2022 | 16126 | 0.010 |
Why?
| | Tomography, X-Ray Computed | 1 | 2014 | 2770 | 0.010 |
Why?
| | Genes, T-Cell Receptor beta | 1 | 2002 | 23 | 0.010 |
Why?
| | Cytotoxicity, Immunologic | 1 | 2002 | 224 | 0.010 |
Why?
| | Reproducibility of Results | 1 | 2009 | 3418 | 0.010 |
Why?
| | T-Lymphocyte Subsets | 1 | 2002 | 420 | 0.010 |
Why?
| | Sequence Analysis, DNA | 1 | 2002 | 778 | 0.010 |
Why?
| | Flow Cytometry | 1 | 2002 | 1165 | 0.010 |
Why?
| | Surveys and Questionnaires | 1 | 2009 | 6085 | 0.010 |
Why?
| | Mice | 1 | 1990 | 18356 | 0.010 |
Why?
| | Infant | 1 | 2002 | 10091 | 0.000 |
Why?
| | Animals | 1 | 1990 | 38102 | 0.000 |
Why?
| | Child, Preschool | 1 | 2002 | 11868 | 0.000 |
Why?
| | Child | 1 | 2002 | 22740 | 0.000 |
Why?
|
|
Striebich's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|